Last chance: Probiota 2019 Early Bird registration ends TODAY!

Probiota 2019​​ will combine the latest insights from science, regulation and business to provide delegates with the ultimate event to bridge the gap between the worlds of business and primary research.

Moving to Copenhagen for its 2019 edition, the congress will explore the frontier of pre-, probiotic and microbiome science, and how that is applied in the commercial world for food, pharma and nutraceutical players everywhere.

Early Bird registration for this industry-leading event ends at midnight today - 31^st​ October. 

Register now to receive a 20% discount on both industry and academic delegate places.​​

The annual event will bring together experts and leaders from global industries and academia together in one place to present top-level insights and provide otherwise impossible networking opportunities.

On the agenda are engaging sessions on the scientific and commercial potential of the fermented foods​ trend, dealing with – and making sense of – big data and bioinformatics​, the importance of our microbiome in metabolism​, plus sessions looking at the latest microbiome start-up trailblazers​ and a deep dive into the growing field of microbiome therapeutics and drug development​.

In addition, don’t miss key updates from the IPA​, alongside regulatory insights​ from top experts, and sessions looking at how proposed taxonomic changes​ will affect your business or research.

Check out the highlights from the 2018 edition of Probiota - held in conjunction with the IPA World Congress.​

We want you!​

Do you want to present your cutting-edge research or state-of-the-art development in the prebiotic, probiotic or microbiome area to a room full of industry-leading experts and top academics?

In addition to its Early Bird offering, the Probiota 2019 is now calling for submission of abstracts​ for this year's event.

Don’t miss your chance to present! Deadline for entries is 30th November 2017.​

We are particularly interested in reports from human intervention studies and welcome abstracts from those engaged in all aspects of microbiome science in academia, industry and consumer health, particularly those representing successful academia-industry interactions.

All abstract submissions​ will be reviewed by the Probiota Scientific Committee made up of leading experts in the fields of microbiome science, probiotic and prebiotic research.

To download the abstract guidelines – and find out how to submit your work - please click HERE​​.

Furthermore, those whose abstracts are accepted will receive a 50% discount on the delegate place.

Key themes announced! ​

While we are still working on the full programme, we are pleased to announce the following topics as key focus areas for the 2019 edition of Probiota.​

Register now to receive a 20% discount on both industry and academic delegate places​. ​

• Measuring the microbiome​ - ​Getting a reliable measure of what our microbiome actually looks like is vital to the future of research and commercial development in the area. During Probiota 2019 we will look at the latest research methods and technologies to sample, count, and analyse the microbiome, including a look at novel biomarkers and techniques that may provide reliable read-outs of our microbiome.​

• The microbiome: Inflammation and metabolism​ - Dysbiosis of the microbiome has been linked to a raft of metabolic and lifestyle diseases. From diabetes to obesity and cardiovascular disease – to name just three. Probiota 2019 will explore the cutting edge research linking diet to microbes, and metabolic conditions – asking what the future has in store for this exciting area.​

• From bugs to drugs: Clinical opportunities & microbiome therapeutics​ –​ The red-hot interest and seemingly boundless opportunities of the microbiome has given rise to intense focus from researchers, investors, and companies working in both the nutraceutical and pharmaceutical space. As start-ups and global healthcare companies alike, look to build innovative pipelines based on microbiome science, and jockey for positioning as commercial interest rockets, Probiota 2019 takes a deep dive into some of the science driving the rapid shifts towards microbiome therapeutics. From cutting-edge clinical science to lessons and insights from investors, innovators and major players in the space, this session will offer the must-have insights for the microbiome therapeutics field.​

• Trailblazers: Start-up and Innovation Focus​ –​ There’s never been a better time to launch a microbiome or probiotic start-up. As major universities look to spin-out and licence key discoveries, global food and pharma businesses open up venture funds and external innovation programmes and incubators to draw innovative entrepreneurs into their orbit – there are rich pickings for microbiome trailblazers in search of money, experience and a global platform for their ideas. But how can you win in a competitive environment? This is your chance to hear from the latest microbiome spin-outs and start-ups, and get top-level insights from experts in innovation, funding and partnering. The session will combine insights from emerging and established microbiome ‘start-ups’ with those of key investors and industry giants looking to partner, invest in and otherwise work with the start-ups and spin-outs in the microbiome area.​
  Together with our innovation panellists, our Trailblazers will discuss the key discoveries, findings and market trends they are tapping into and shine a spotlight on some of the opportunities (and pitfalls) that are out there.​

• Real food and drink: The rise of fermented foods​ –​ The probiotic and prebiotic categories have traditionally been focused on dietary supplements and functional foods, but with a growing trend for fermented foods and drinks like kimchi, kefir and kombucha, we ask what the science says about these foods, and what companies are doing to exploit these new market opportunities.​
• Making sense of ‘big data’​ –​ The sheer amount of data that can be captured by researchers and companies looking to measure the microbiome and health is vast – but making sense of the data can be tough. This session looks at new and existing methods to manage and analyse ‘big data’ - from the latest learnings in bioinformatics and systems biology to insights on AI and machine learning. This session will bring together lessons on how to tap into the latest technologies in data management and analysis, and asks what the future the future of ‘big data’ may look like.​
• From population to personalisation: What can the microbiome show us? –​ Many research projects and company pipelines are looking to leverage population-level data to gain a better understanding of how and why our gut bacteria differ – and whether shifts to our microbiota can cause our health to alter. This session looks to gain updates on major population-level studies but also looks at how these huge population sets can begin to inform a more personal understanding of the microbiome. It will also explore whether using new technologies, ‘big data’, and wearable and digital health revolution are coming together to help personalise our health, and manage disease – asking where are the opportunities for probiotics, prebiotics and other microbiome modulators in this space?​
• Taxonomy updates to the Lactobacillus genus: A situational update –​ The updating and re-naming of organisms is a normal and integral process, that continually happens as the body of science is updated with exciting new data from 16S rRNA, whole genome sequencing, and the discovery of new species. As this process happens, it has been suggested that the genus “Lactobacillus” should be updated. While name changes in this genus have occurred frequently in the past without too many negative consequences, until now re-naming has never been suggested so broadly, and has never touched species with such considerable economic importance to the industry. This session looks to outline the key changes being made, and discuss the potential commercial, research and regulatory implications.​

• The influence of the microbiome in ageing
• The importance and influence of the skin microbiome
• The microbiome in drug delivery
• Improving probiotic production methods
• Delivery technologies – from nutraceuticals to drugs
• The Microbiome and cancer
• Nutritional psychiatry: The role of the microbiome in anxiety, depression and mood
• Clinical outcomes for probiotics and prebiotics
• Next-gen probiotics
• Consumer, retailer, and online opportunities
• Regulatory updates
• Branding and marketing
• Packaging innovations